Capmatinib
Capmatinib
Capmatinib (pronounced kap-ma-TIN-ib) is a kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) that is locally advanced or metastatic. It is specifically used for patients with NSCLC whose tumors have a mutation in the MET gene, also known as MET exon 14 skipping.
Etymology
The name "Capmatinib" is derived from the chemical name of the drug, which is 5-[(1R)-1-(2,3-Dihydro-1H-inden-1-yl)ethyl]-8-(1-methyl-1H-pyrazol-4-yl)-2-[[4-(4-methylpiperazin-1-yl)piperidin-1-yl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one. The "Cap" comes from the first three letters of the chemical name, the "matin" is derived from the term "matinée", which refers to a morning performance, and the "ib" is a common suffix used in the names of kinase inhibitors.
Usage
Capmatinib is administered orally in the form of a tablet. The recommended dosage is 400 mg twice daily, taken approximately 12 hours apart. The drug should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal.
Side Effects
Common side effects of Capmatinib include nausea, vomiting, fatigue, and shortness of breath. Serious side effects can include pneumonitis, hepatotoxicity, and renal toxicity.
Related Terms
External links
- Medical encyclopedia article on Capmatinib
- Wikipedia's article - Capmatinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski